Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLA2001 Booster in Adults Primed with Inactivated COVID-19 Vaccine
NCT05545683Phase 3Withdrawn
- Sponsor
- Centro de Estudios en Infectología Pediátrica
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Viral Vector Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of VLA2001 in coronavirus disease 2019 (COVID-19), sponsored by Centro de Estudios en Infectología Pediátrica. Primary endpoints: Geometric Mean Titer (GMT) fold-rise for neutralizing antibodies at Day 16 and Adverse events at Day 8. Planned start Dec 2022; status: withdrawn.
02
Drugs
VLA2001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05545683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05545683.